Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Falkson CI, et al. Among authors: coates as. J Clin Oncol. 1998 May;16(5):1743-51. doi: 10.1200/JCO.1998.16.5.1743. J Clin Oncol. 1998. PMID: 9586887 Clinical Trial.
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, Price KN, Coates AS, Hürny C, Bernhard J, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A. Crivellari D, et al. Among authors: coates as. J Clin Oncol. 2000 Apr;18(7):1412-22. doi: 10.1200/JCO.2000.18.7.1412. J Clin Oncol. 2000. PMID: 10735888 Clinical Trial.
Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J. Byrne MJ, et al. Among authors: coates as. J Clin Oncol. 1997 Sep;15(9):3141-8. doi: 10.1200/JCO.1997.15.9.3141. J Clin Oncol. 1997. PMID: 9294477 Clinical Trial.
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.
Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg SB, Cortes-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A; International Breast Cancer Study Group. Colleoni M, et al. Among authors: coates as. J Clin Oncol. 2001 Nov 1;19(21):4141-9. doi: 10.1200/JCO.2001.19.21.4141. J Clin Oncol. 2001. PMID: 11689582 Clinical Trial.
Identifying breast cancer patients at high risk for bone metastases.
Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Rudenstam CM. Colleoni M, et al. Among authors: coates as. J Clin Oncol. 2000 Dec 1;18(23):3925-35. doi: 10.1200/JCO.2000.18.23.3925. J Clin Oncol. 2000. PMID: 11099322
257 results